Compared with warfarin , apixaban resulted in a consistent reduction in stroke or systemic embolism in East Asian ( hazard ratio [ HR ] 0.74 , 95 % CI 0.50-1 .10 ) and non-East Asian ( HR 0.81 , 95 % CI 0.66-0 .99 ) patients ( interaction P = .70 ) .